Stockreport

NantKwest and ImmunityBio to Initiate a Phase 2 Study of Immunotherapy for Metastatic Pancreatic Cancer

NANTKWEST  (NK) 
Last nantkwest earnings: 3/25 04:09 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.nantkwest.com
PDF Open-label, randomized Phase 2 study will evaluate combination immunotherapy, including NantKwest’s PD-L1 tumor-targeted natural killer cells and ImmunityBio’s IL-15 sup [Read more]